Skip to content
RetailNews Asia
General

Pharma industry growth slows down

By Mei Ling Tan
1 min read
Pharma industry growth slows down
Pharma industry growth slows down

The pharmaceutical industry’s revenues rose by just 3 percent in 2020, down from an average of 11.8 percent in the previous five years.

But it was a notable year for mergers and acquisitions. According to analysts at SSI Securities, the total value of M&A was VND1.68 trillion ($73 million) last year and involved a number of foreign investors.

In May, South Korean conglomerate SK Group, which makes anti-cancer and cardiovascular drugs and mental health medications, paid VND920 billion to acquire a 25 percent stake in Imexpharm Pharmaceutical Joint Stock Company.

In August, Japan’s Aska Pharmaceutical acquired a 24.9 percent stake in Ha Tay Pharmaceutical Joint Stock Company (Hataphar).

In December, German generic drugmaker Stada paid VND400 billion to increase its stake in Pymepharco by 6 percent to nearly 76 percent.

SSI analysts estimated the pharmaceutical industry to grow by 15 percent in 2021 mainly due to a rapidly aging population and rising incomes.

Weekly Briefing

Asia's retail intelligence, in your inbox

We respect your inbox as much as we value your time. That's why we only send carefully curated weekly updates, packed with the most relevant news, trends, and insights from the retail industry across Asia and beyond.

Protected by a quick human check. No spam, ever.